Search clinical trials for: Thymosin Beta 4

Total 9873 results

RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Myocardial Infarction | Myocardial Ischemia

United States
RegeneRx Biopharmaceuticals, Inc.

Terminated

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Epidermolysis Bullosa
RegeneRx Biopharmaceuticals, Inc.

Completed

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Pressure Ulcers

United States
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

ST Elevation Myocardial Infarction | Acute Myocardial Infarction | STEMI
RegeneRx Biopharmaceuticals, Inc.
sigma-tau i.f.r. S.p.A.

Completed

Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers (SSVS)

Venous Stasis Ulcers

Italy, Poland
ReGenTree, LLC
PPD

Terminated

A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

Diabetes

United States
ReGenTree, LLC

Completed

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

Dry Eye Syndrome

United States
ReGenTree, LLC

Completed

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 (ARISE-3)

Dry Eye | Dry Eye Syndromes

United States
ReGenTree, LLC

Completed

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

Dry Eye Syndrome

United States
ReGenTree, LLC

Recruiting

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Neurotrophic Keratopathy

United States
Michigan Cornea Consultants, PC
Kresge Eye Institute

Completed

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

Dry Eye | Sjogren's Syndrome | Graft vs. Host Disease

United States
ReGenTree, LLC
ORA, Inc.

Completed

Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye

Dry Eye | Dry Eye Syndrome
Zhigang Zhang

Unknown

Thymosin-α1 in Cancer-Related Fatigue

Quality of Life | Cancer Related Fatigue

China
University Hospital, Toulouse

Completed

Dopaminergic Loss and Pain in Parkinson's Disease

Pain | Parkinson's Disease

France
Beijing Northland Biotech. Co., Ltd.

Completed

A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers

Healthy

China
Beijing Northland Biotech. Co., Ltd.

Completed

A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers

Healthy

China
Weiqin Li
Jiangsu Province Hospital of Traditional Chinese Medicine; The First Affiliated... and other collaborators

Completed

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis (TRACE)

Pancreatitis, Acute Necrotizing

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk...

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
University of Tartu

Completed

Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer

Thyroid Cancer

Estonia
University Hospital Freiburg

Completed

Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation

Hyperlipidemias | Hypopituitarism | Secondary Hypothyroidism

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic... and other conditions

United States
Sun Yat-sen University

Active, not recruiting

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

Thymoma and Thymic Carcinoma

China
Rambam Health Care Campus

Unknown

Thyroid Hormones Treatment in Asthma Exacerbation (THINAS)

Asthma

Israel
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (VITAL)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic Syndrome | Myeloid Sarcoma | Acute Myeloid Leukemia With Multilineage Dysplasia

United States
Steven E. Coutre
National Cancer Institute (NCI)

Terminated

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia

United States, Canada
National Cancer Institute (NCI)

Suspended

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia

United States
University of Washington
National Cancer Institute (NCI)

Completed

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-2

United States
Fudan University

Recruiting

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Stage III Colorectal Cancer | Stage II Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Long-term Prognosis of Patients With Sepsis After Immunotherapy

Long-term Effects of Thymosin Alpha 1 Treatment
RenJi Hospital

Unknown

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

Osteoporotic Pain

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Refnot-Pharm Ltd

Completed

Effect of Refnot on Immunity in Cancer Patients (R-2)

Solid Tumor
National Cancer Institute (NCI)
Childrens Oncology Group (COG); LLS PedAL LLC

Recruiting

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane

Down Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic...

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome With Isolated Del(5q)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome

United States
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc; Whittier Foundation

Terminated

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Myeloproliferative Neoplasm | Myeloid Sarcoma | Blasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

United States
University Of Perugia

Unknown

Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies

Hematological Malignancies

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States

Search clinical trials for: Thymosin Beta 4

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations